Johnson & Johnson (NYSE:JNJ) shares sold by Mayflower Financial Advisors LLC

Mayflower Financial Advisors LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 11.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,247 shares of the company’s stock after selling 2,195 shares during the period. Mayflower Financial Advisors LLC’s holdings in Johnson & Johnson were worth $2,375,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Inçalta Capital LLC purchased a new stake in shares of Johnson & Johnson in the second quarter worth approximately $27,000. Christopher J. Hasenberg Inc purchased a new stake in Johnson & Johnson in the 1st quarter worth about $31,000. MFA Wealth Advisors LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at $43,000. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at $44,000. Finally, Grayhawk Investment Strategies Inc. boosted its position in Johnson & Johnson by 528.6% during the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after purchasing an additional 259 shares during the period. 69.55% of the shares are currently held by hedge funds and other institutional investors.

Insider buying and selling

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC’s website. 0.16% of shares are owned by company insiders.

Johnson & Johnson trading down 0.4%

NYSE:JNJ opened at $164.41 on Friday. The company has a market cap of $395.68 billion, a PE ratio of 10.25, a P/E/G ratio of 2.73 and a beta of 0.52. The company’s 50-day moving average is $157.57, and its two-hundred-day moving average is $153.83. The company has a quick ratio of 0.85, a current ratio of 1.07, and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. In the same quarter last year, the company posted earnings of $2.80 per share. The company’s revenue rose 4.3% year-on-year. On average, analysts predict that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson announces dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. This represents a dividend of $4.96 on an annualized basis and a dividend yield of 3.02%. The ex-dividend date is Tuesday, August 27. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Analysts on Wall Street are forecasting an increase

JNJ has been the subject of several recent research reports. Sanford C. Bernstein upped their price objective on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Goldman Sachs Group dropped their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. TD Cowen cut their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Finally, Morgan Stanley upped their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research report on Thursday. July 18. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $173.21, according to MarketBeat.com.

Read our latest report on Johnson & Johnson

About Johnson & Johnson

(Free report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.

Featured stories

Want to see what other hedge funds JNJ owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Free Report).

Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.